In trials of amyloid-lowering drugs for Alzheimer’s disease (AD), differential eligibility may contribute to under-inclusion of racial and ethnic underrepresented groups. We examined plasma amyloid beta 42/40 and positron emission tomography (PET) amyloid eligibility for the ongoing AHEAD Study preclinical AD program (NCT04468659).
Univariate logistic regression models were used to examine group differences in plasma and PET amyloid screening eligibility.
Of 4905 participants screened at time of analysis, 1724 were plasma eligible to continue in screening: 13.3% Hispanic Black, 24.7% Hispanic White, 20.8% non-Hispanic (NH) Asian, 24.7% NH Black, and 38.9% NH White. Plasma eligibility differed across groups in models controlling for covariates (odds ratio from 1.9 to 4.0 compared to the NH White reference group, P < 0.001). Among plasma eligible participants, PET eligibility did not differ by group.
These results suggest that prevalence of brain amyloid pathology differed, but that eligibility based on plasma was equally effective across racial and ethnic group members.

Plasma amyloid eligibility is lower in underrepresented racial and ethnic groups.
In plasma eligible adults, positron emission tomography eligibility rates are similar across race and ethnicity.
Plasma biomarker tests may be similarly effective across racial and ethnic groups.

If you do not see content above, kindly GO TO SOURCE.
Not all publishers encode content in a way that enables republishing at Neuro.vip.

This post is Copyright: Doris Patricia Molina‐Henry,
Rema Raman,
Andy Liu,
Oliver Langford,
Keith Johnson,
Leona K. Shum,
Crystal M. Glover,
Shobha Dhadda,
Michael Irizarry,
Gustavo Jimenez‐Maggiora,
Joel B. Braunstein,
Kevin Yarasheski,
Venky Venkatesh,
Tim West,
Philip B. Verghese,
Robert A. Rissman,
Paul Aisen,
Joshua D. Grill,
Reisa A. Sperling | April 17, 2024

Wiley: Alzheimer’s & Dementia: Table of Contents